Domènech E - Search Results

1

Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis.

Bamias G, Zampeli E, Domènech E. Bamias G, et al. Among authors: domenech e. Expert Rev Gastroenterol Hepatol. 2022 Aug;16(8):721-735. doi: 10.1080/17474124.2022.2100759. Epub 2022 Jul 19. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35833363 Review.

2

Cytomegalovirus infection in patients with inflammatory bowel disease.

Vega R, Bertrán X, Menacho M, Domènech E, Moreno de Vega V, Hombrados M, Cabré E, Ojanguren I, Gassull MA. Vega R, et al. Among authors: domenech e. Am J Gastroenterol. 1999 Apr;94(4):1053-6. doi: 10.1111/j.1572-0241.1999.01013.x. Am J Gastroenterol. 1999. PMID: 10201482

3

Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.

Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA; Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Domènech E, et al. Aliment Pharmacol Ther. 2004 Dec;20(11-12):1347-52. doi: 10.1111/j.1365-2036.2004.02288.x. Aliment Pharmacol Ther. 2004. PMID: 15606397 Free article.

4

6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine.

Domènech E, Nos P, Papo M, López-San Román A, Garcia-Planella E, Gassull MA. Domènech E, et al. Scand J Gastroenterol. 2005 Jan;40(1):52-5. doi: 10.1080/00365520410009492. Scand J Gastroenterol. 2005. PMID: 15841714

5

Inflammatory bowel disease: current therapeutic options.

Domènech E. Domènech E. Digestion. 2006;73 Suppl 1:67-76. doi: 10.1159/000089781. Epub 2006 Feb 8. Digestion. 2006. PMID: 16498254 Review.

6

Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice.

Domènech E, Mañosa M, Navarro M, Masnou H, Garcia-Planella E, Zabana Y, Cabré E, Gassull MA. Domènech E, et al. J Clin Gastroenterol. 2008 Apr;42(4):395-9. doi: 10.1097/MCG.0b013e31802e6875. J Clin Gastroenterol. 2008. PMID: 18277899

7

Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.

Domènech E, Zabana Y, Mañosa M, Garcia-Planella E, Cabré E, Gassull MA. Domènech E, et al. J Clin Gastroenterol. 2010 Jan;44(1):34-7. doi: 10.1097/MCG.0b013e3181962dfa. J Clin Gastroenterol. 2010. PMID: 19417683

8

[Apheresis in inflammatory bowel disease].

Nos P, Domènech E. Nos P, et al. Among authors: domenech e. Gastroenterol Hepatol. 2009 Aug-Sep;32(7):509-18. doi: 10.1016/j.gastrohep.2009.01.183. Epub 2009 Jul 15. Gastroenterol Hepatol. 2009. PMID: 19608298 Review. Spanish.

9

Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.

Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Zabana Y, et al. Among authors: domenech e. Aliment Pharmacol Ther. 2010 Mar;31(5):553-60. doi: 10.1111/j.1365-2036.2009.04206.x. Epub 2009 Nov 30. Aliment Pharmacol Ther. 2010. PMID: 20002026 Free article.

10

[Portal hypertension in patients with inflammatory bowel disease].

Leal-Valdivieso C, Naves JE, Mañosa M, Zabana Y, Cabré E, Domènech E. Leal-Valdivieso C, et al. Among authors: domenech e. Gastroenterol Hepatol. 2010 Apr;33(4):297-302. doi: 10.1016/j.gastrohep.2009.12.003. Epub 2010 Mar 4. Gastroenterol Hepatol. 2010. PMID: 20206413 Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

446 results

Search Page